Restoration of HBV-specific CD8⁺ T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-α therapy.

ABSTRACT: Patients with chronic hepatitis B (CHB) undergoing interferon (IFN)-α-based therapies often exhibit a poor HBeAg serological response. Thus, there is an unmet need for new therapies aimed at CHB. This study comprised two clinical trials, including 130 CHB patients, who were treatment-naïve; in the first, 92 patients were systematically analyzed ex vivo for interleukin-2 receptor (IL-2R) expression and inhibitory molecules expression after receiving Peg-IFN-α-2b therapy. In our second clinical trial, 38 non-responder patients, in whom IFN-α therapy had failed, were treated with or without low-dose IL-2 for 24 weeks. We then examined the hepatitis B virus (HBV)-specific CD8⁺ T-cell response and the clinical outcome, in these patients. Although the majority of the participants unde

SUBMITTER: Wang D 

PROVIDER: S-EPMC8569154 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature